TrialThe lancet. Diabetes & endocrinology2017

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Christopher Sorli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.